Hemospermia is usually a symptom of urological relevance, however it may have also a medical and hematological significance and has been reported in congenital or acquired bleeding disorders. Because of this symptom’s negative psychological impact on the patient, it is likely that the condition is underplayed and therefore underdiagnosed. During the years 1967–2003 we had the opportunity to see 3 patients with hemospermia on a congenital bleeding disorder: a patient with hemophilia A, another with prothrombin deficiency and finally a patient with von Willebrand disease type I. All patients were heterosexual. In all instances the course was benign since it required administration of substitution therapy on only 2 occasions. Rest and abstinence from sexual activity appeared to be helpful. The first patient had other signs and symptoms compatible with the diagnosis of urethritis due to Escherichia coli and he underwent a course of antibiotic therapy. The other 2 cases appeared to be idiopathic since no associated condition was found. Urinary cytology, rectal examination, prostate sonography and prostate-specific antigen were normal in all cases. The rarity of hemospermia in congenital bleeding disorders remains unexplained, although the strong perineal and sphincter muscles may exercise a compressive hemostatic effect which could prevent or reduce bleeding.

Keywords:
Hemospermia, Coagulation disorders, Bleeding
1.
Ahmad I, Krishna NS: Hemospermia. J Urol 2007;177:1613–1618.
2.
Ameur A, Touiti D, Jira H, el Alami M, Boumdin H, Abbar M: Les hémospermies: orientation diagnostique et thérapeutique. A propos de sept cas. Ann Urol (Paris) 2002;36:74–80.
3.
Furuya S, Ogura H, Saitoh N, Tsukamoto T, Kumamoto Y, Tanaka Y: Hematospermia: an investigation of the bleeding site and underlying lesions. Int J Urol 1999;6:539–548.
4.
Game X, Fournier R, Berlizot P, Houlgatte A: L’hémospermie. Prog Urol 2002;12:18–21.
5.
Ganabathi K, Chadwick D, Feneley RC, Gingell JC: Hemospermia. Br J Urol 1992;69:225–230.
6.
Munkelwitz R, Krasnokutsky S, Lie J, Shah SM, Bayshtok J, Khan SA: Current perspectives on hematospermia: a review. J Androl 1997;18:6–14.
7.
Papp GK, Kopa Z, Szabó F, Erdei E: Aetiology of hemospermia. Andrologia 2003;35:317–320.
8.
Singh I, Sharma N, Singh N, Gangas R: Hematospermia (ejaculatory duct calculus) – an unusual cause. Int Urol Nephrol 2003;35:517–518.
9.
Suzuki K, Nishimi D, Morioka H, Takanami M: Hematospermia associated with congenital arteriovenous malformation of internal iliac vessels. Int J Urol 2007;14:370–372.
10.
Torigian DA, Ramchandani P: Hematospermia: imaging findings. Abdom Imaging 2007;32:29–49.
11.
Girolami A, Lazzarin M, Scarpa R, Brunetti A: Congenital hypoprothrombinemia. A case report with some considerations on the behaviour of T.G.T, in this condition. Coagulation 1970;3:45–53.
12.
Girolami A: The hereditary transmission of congenital ‘true’ hypoprothrombinemia. Brit J Haematol 1971;21:695–703.
13.
Girolami A, Luzzatto G, Varvarikis C, Pellati D, Sartori R, Girolami B: Main clinical manifestations of a bleeding diathesis: an often disregarded aspect of medical and surgical history taking. Haemophilia 2005;11:193–202.
14.
Pollmann H, Richter H, Jürgens H: Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors. Thromb Haemost 1998;79:1213–1214.
15.
Racoosin JA, Kessler CM: Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia 1999;5:266–269.
16.
Sauleda S, Martorell M, Esteban JI, Tural C, Ruiz I, Puig L, Esteban R, Guardia J, Vargas V: Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an haemophilia unit during a decade. Haemophilia 2006;12:228–236.
17.
Stanworth SJ, Bolton MJ, Hay CR, Shiach CR: Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 1998;4:109–114.
18.
Yazdanpanah Y, Viget N, Cheret A, Guerroumi H, Gerard Y, Ajana F, Caron J, Mouton Y: Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir. AIDS 2003;17:2397–2399.
19.
Yee TT, Amrolia PJ, Lee CA, Mir N, Giangrande PL: Protease inhibitors and unusual bleeding in hemophiliacs. Haemophilia 1997;3:220–221.
20.
Hollmig KA, Beck SB, Doll DC: Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors. Eur J Med Res 2001;6:112–114.
21.
Keeling PJ, Lawson CS: Haemospermia: a complication of thrombolytic therapy. Br J Hosp Med 1990;44:244.
22.
Lemesh RA: Case report: recurrent hematuria and hematospermia due to prostatic telangiectasia in classic von Willebrand’s disease. Am J Med Sci 1993;306:35–36.
23.
Emori Y, Sakugawa M, Niiya K, Kiguchi T, Kojima K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Tanimoto M, Yamasaki R, Ohara N, Harada M: Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002;13:555–559.
24.
Yu HH, Wong KK, Lim TK, Leong CH: Clinical study of hemospermia. Urology 1977;10:562–563.
25.
Mauser-Bunschotten EP, De Knecht-van Eekelen A, Smit L: Rare Bleeding in Haemophilia. Utrecht, Van Creveld Klinik UML, 2002.
26.
Levine MN, Raskob G, Landefeld S, Hirsh J: Hemorrhagic complications of anticoagulant treatment: Chest 1995;108(4 suppl): 276S–290S.
27.
Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C: Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007;70:501–505.
28.
Leary F: Hematospermia. J Fam Pract 1975;2:185–186.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.